Genesis Health review

The FDA letter belongs in the first decision

FDA issued warning letter 721451 to Genesis Health International Inc. dba Genesis. It concerns false or misleading claims about compounded semaglutide and tirzepatide offered on Genesis Health's website. The domain, Boynton Beach address and contact information connect the letter to this service, rather than to another business that happens to use the name Genesis.

A prospective patient should distinguish that action from a medicine recall or a conclusion about every possible patient outcome. The letter identifies problems with this seller’s claims and labeling. A broad treatment menu or an attractive website does not answer those concerns; the actual product, prescriber, pharmacy and current disclosures still need to be understood before enrollment.

The visible prices belong to other products

Genesis does not publish a GLP-1 treatment price in its public menu. Figures such as $175 for a first month of sermorelin and $165 for NAD+ refer to different products. Neither establishes a semaglutide or tirzepatide price, and neither should be used to estimate the cost of a GLP-1 program simply because it appears near the weight-loss material.

This leaves the important affordability questions unanswered before assessment. Ask for a full quote for the intended medication and dose, including clinical service, any required membership, the pharmacy charge, supplies and shipping. Also ask how much of the payment is introductory and what renews. Until the seller provides those details, there is no reliable monthly treatment amount to compare with an openly priced competitor.

Branded and compounded routes need separate quotes

The product menu names compounded semaglutide and tirzepatide alongside brand Ozempic, Zepbound and Wegovy. That provides several routes to discuss with a clinician, but it does not establish that every route is available to a particular patient or has the same financial structure. A branded product and a compounded preparation should remain separate choices in the treatment and cost conversation.

If the clinician recommends a brand, obtain the exact product, dose, supply and medication price. If a compounded preparation is proposed, ask which pharmacy will dispense it and how the formulation is identified. The presence of a recognizable brand name elsewhere in the catalog should not be used as evidence that an unnamed compounded offer carries the same approval status or supporting evidence.

The assessment is an entry point, not the full service description

Genesis describes a short online health assessment. That may make beginning the process convenient, but a short questionnaire does not tell a reader how clinical follow-up is arranged, how much contact is included or how a medication change is handled. Ask who reviews the submission and how the clinician will communicate a recommendation before assuming that a prescription or delivery will follow.

The public information does not state a complete service area or publish cancellation terms. Those gaps matter when a treatment price is also unavailable. Confirm state eligibility before making plans around the program, and ask when payment becomes non-refundable or an order becomes committed. Silence on cancellation should not be interpreted as either a flexible policy or a prohibition on stopping; it means the condition needs a specific answer.

A clearer offer is necessary before a financial comparison

Genesis may be relevant to someone who wants to discuss both brand and compounded options through one service. Its present public disclosures make it harder to judge for someone who needs a predictable budget and clear exit terms before sharing clinical details. A listed medication is evidence of the menu, not a complete order or a promise of access.

The next useful step is a written offer that identifies the prescribed product, treating practice, dispensing pharmacy, charge interval and cancellation conditions. Read that offer alongside the FDA letter concerning this company’s own website. The unrelated sermorelin and NAD+ prices do not fill the GLP-1 pricing gap, and a short assessment should not be allowed to do the work of the missing financial explanation.